FDA approves at-home chlamydia, gonorrhea, trichomoniasis test for women
Visby Medical Women's Sexual Health Test can be taken by those with or without symptoms,and delivers results in about 30 minutes, the FDA said in a news release.
This is the first diagnostic test for chlamydia, gonorrhea and trichomoniasis that can be bought without a prescription and done entirely at home. Last year, the FDA also authorized an at-home syphilis test.
'Home tests can give people information about their health from the privacy of their home. This can be particularly important for sexual health tests for which patients may experience fear or anxiety, possibly resulting in delayed diagnosis or treatment,'Courtney Lias, Ph.D., director of the Office of In Vitro Diagnostic Devices in the FDA's Center for Devices and Radiological Health, said in a statement. 'Expanding access to tests for sexually transmitted infections is an important step toward earlier and increased diagnosis, which can result in increased treatment and reduced spread of infection.'
Tariffs will drive up prices of everyday goods from coffee to toys
The Visby Medical Women's Sexual Health Test, according to the FDA, correctly identified 98.8% of negative and 97.2% of positive Chlamydia trachomatis samples; 99.1% of negative and 100% of positive Neisseria gonorrhoeae samples; and 98.5% of negative and 97.8% of positive Trichomonas vaginalis samples, according to the FDA.
Adam de la Zerda, the founder and CEO of Visby Medical, said the test was in development for 12 years.
'This approval is not just a milestone for Visby Medical but marks a transformative moment in medical diagnostics,' de la Zerda said in a statement. 'We've achieved something incredible; our palm-sized, single-use PCR test is simple to use and replaces a bulky, large, expensive laboratory instrument.'
The test is single-use and includes a collection kit and powered testing device. Once the test is complete, results are shown on the Visby Medical App.
The Visby Medical Women's Sexual Health Test is a single use, at home test, that includes a collection kit (self-collected vaginal swab) and a powered testing device, which communicates securely to the Visby Medical App, which displays results when the test is complete.
More than 600,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the U.S. in 2023, the Centers for Disease Control and Prevention's Sexually Transmitted Infections (STI) Surveillance Report states. Trichomoniasis affected about 2.6 million people in 2021, per the CDC.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic). PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria. Additional U.S. prescribing information about PIVYA can be found at 'We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,' said Tom Hadley, President and CEO of UTILITY therapeutics. 'With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.' The UTILITY therapeutics Ltd. Board of Directors and Observers includes: 'The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic's strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,' said Craig Salmon, President of Alembic Pharmaceuticals, Inc. 'PIVYA will further enhance Alembic's ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4th quarter of 2025.' 'I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,' said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. 'With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.' About PIVYA (pivmecillinam oral tablets 185mg) PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from 8×10-8 to 2×10-5 when exposed to 32-256 times MIC. PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%). PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥105 colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen. Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population) Clinical Cure Rates (Micro-ITT Population) Microbiological Response Rates (Micro-ITT Population) Contraindications Warnings and precautions About UTILITY therapeutics Ltd. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting. For more information, contact David Cobb, Alembic Pharmaceuticals [email protected] 908-552-583 SOURCE: Utility Therapeutics Ltd. press release
USA Today
2 hours ago
- USA Today
How to keep your pets calm during Fourth of July fireworks
Get out the grill and prepare to celebrate Independence Day with BBQs, lawn chairs, and delicious food! The Fourth of July is perfect for gathering with friends, family, and pets. Just remember, while fireworks are fun for many, they can be frightening for some animals. Loud noises like fireworks or thunderstorms are the cause of nearly one in five lost pets, a survey from the American Society for the Prevention of Cruelty to Animals found. While we celebrate our Independence Day, here's how to keep your four-legged friends safe and happy: Petting your dog If possible, your dog should stay home with at least one human so it can be reassured if it gets anxious. Stay with your pet in a room that has minimal windows and play soft music or a movie to distract from fireworks and other noises. A little affection goes a long way – one of the best ways to calm your dog down is to give it strong, firm pats to let it know you're there, says veterinarian Diana Watkins, who owns 143 Veterinary Services in Massachusetts. Thundershirt You can try anxiety-reducing devices like a Thundershirt, which acts like a weighted blanket to soothe your dog. Medication For extra-nervous dogs, there are situational anxiety medications your vet can prescribe. They can be helpful during loud sensory events like thunderstorms and fireworks or when you're leaving your dog alone for longer than normal. Watkins advises giving your dog only veterinary-grade products because over-the-counter anti-anxiety and CBD supplements are often not FDA-regulated and can be harmful to your pup. Collar with ID Make sure your pet has an ID tag on at all times, or invest in a GPS locator for its collar if your pet isn't microchipped. Take a walk before nighttime It's a good idea to time walks earlier in the day before the fireworks start. Keep your dog on lead if you think fireworks will be set off. Consider Hiring a Trainer If fireworks and fear is impacting your animal, you can consider hiring a trainer. Working with a trainer of behavior consultant to desensitize your dog to fireworks gradually. It's never to late to plan for the next fireworks event. Sources: USA TODAY Network reporting and research; American Kennel Club
Business Wire
2 hours ago
- Business Wire
Precisio Biotix Therapeutics, Inc. (Precisio) Announces Dosing of a First Patient with ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection
DOVER, Del.--(BUSINESS WIRE)-- Precisio announced a first-in-man dosing of its staph lysin called ClyO (LYSG101) to a patient with a prosthetic joint infection that had not responded to other treatments. The FDA approved this treatment under a compassionate care IND filed by The patient appears to have tolerated the treatment without any adverse events. It is too early to assess full efficacy, but this is certainly a significant step toward providing additional options to patients, particularly when traditional treatments have failed. Dr. Raymond Schuch, VP, Director of US Operations, notes, 'Our sole company focus is the systematic engineering of native lysins and generation of drug-like, optimized and engineered lysins vs. antimicrobial-resistant human pathogens that are associated with high unmet medical needs. Our team possesses unique experience of developing these lysins and transitioning lysins into clinical studies and into patients. To date, our efforts have focused on respiratory, skin, and vaginal infections. We are excited to add prosthetic joint infections to the portfolio of infections we think that we can effectively treat.' Mark Engel, Founder and CEO of Precisio said, 'We are a platforms plus products company. The key to developing best-in-world lysins is that we use multiple self-developed high-tech proprietary tools. These include tools in bioinformatics, machine-learning, and AI (Zeus™-LysiThru™). We are now at a point where we think we can develop lysin products against many infections including those resistant to standard antibiotics. This patient at Mayo Clinic is the first of what we hope are many examples that we announce in the coming months. Doctors around the globe are anxious to start using our treatments on a compassionate basis since large numbers of patients are not responding to existing treatments.' Dr. Assaf Raz, VP of Research and Development noted: 'Drug-resistant infections are a pressing global health issue, causing at least 700,000 deaths each year. Without decisive action, this number could rise to 10 million annually by 2050, according to the UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance. Our research team is dedicated to developing new lysin therapeutics for large areas of need that bypass antibiotic resistance. We are highly encouraged that our technologies allow us to rapidly create effective solutions for multidrug-resistant pathogens, combating resistant infections and improving patient outcomes.' Mr. Engel summarizes that, 'The engineered lysins we are developing will have a tremendous impact as additional tool for treating and preventing infections. We think that our lysins will be effective against both gram-positive and gram-negative bacteria. Because we are so efficient in developing them, we will be able to produce our lysins in highly stable formulations with low cost-of-goods, thereby making them available to both developed markets and in the LMIC markets. This presents an opportunity to dramatically change health outcomes around the globe. We are now seeking both strategic and financial support to move forward more rapidly. Our team is highly motivated since we know that every day wasted means lives lost.' About Lysins: Lysins are members of a promising new class of antimicrobials - direct lytic agents. Unlike traditional antibiotics, lysins actively hydrolyze the bacterial cell wall, causing extremely rapid lysis and cell death. Due to this unique mechanism of action, lysins are targeted to specific pathogens, can effectively degrade biofilms, and are effective against bacteria resistant to traditional antibiotics. Critically, unlike traditional antibiotics, they do not cause bacterial resistance. About Precisio Biotix Therapeutics Inc. ( Precisio is a US clinical stage biotech company creating lower-cost novel precision engineered biological antibacterials, with an initial focus on respiratory, skin, lung, and prosthetic joint infections. Precisio is a platform-plus-product company (Rx and consumer). The Company has additional R&D operations in India, China, and the UK. Management has had multiple previous successful exits and currently seeks strategic partners for all aspects of the business. Recent news includes (1) a grant award from the Gates Foundation for the development of lysins to treat Bacterial Vaginosis and (2) regulatory approval of a topical Lysin in the EU.
